BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38615173)

  • 21. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.
    Heller G; Topakian T; Altenberger C; Cerny-Reiterer S; Herndlhofer S; Ziegler B; Datlinger P; Byrgazov K; Bock C; Mannhalter C; Hörmann G; Sperr WR; Lion T; Zielinski CC; Valent P; Zöchbauer-Müller S
    Leukemia; 2016 Sep; 30(9):1861-8. PubMed ID: 27211271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
    Asimakopoulos FA; Shteper PJ; Krichevsky S; Fibach E; Polliack A; Rachmilewitz E; Ben-Neriah Y; Ben-Yehuda D
    Blood; 1999 Oct; 94(7):2452-60. PubMed ID: 10498618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible prediction of myeloid and lymphoid crises in chronic myelocytic leukemia at onset by determining the methylation status of the major breakpoint cluster region.
    Ge XQ; Tanaka K; Mansyur A; Tazawa H; Iwato K; Kyo T; Dohy H; Kamada N
    Cancer Genet Cytogenet; 2001 Apr; 126(2):102-10. PubMed ID: 11376802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
    Li Z; Luo J
    Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
    J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
    Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
    Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia.
    Zhou JD; Wang YX; Zhang TJ; Yang DQ; Yao DM; Guo H; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
    Biochem Biophys Res Commun; 2015 Aug; 463(4):1250-6. PubMed ID: 26086097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.
    Koschmieder S; Vetrie D
    Semin Cancer Biol; 2018 Aug; 51():180-197. PubMed ID: 28778403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting the role of aberrant DNA methylation in human leukaemia.
    Amabile G; Di Ruscio A; Müller F; Welner RS; Yang H; Ebralidze AK; Zhang H; Levantini E; Qi L; Martinelli G; Brummelkamp T; Le Beau MM; Figueroa ME; Bock C; Tenen DG
    Nat Commun; 2015 May; 6():7091. PubMed ID: 25997600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GPX3 promoter is methylated in chronic myeloid leukemia.
    Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
    Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JunB gene expression is inactivated by methylation in chronic myeloid leukemia.
    Yang MY; Liu TC; Chang JG; Lin PM; Lin SF
    Blood; 2003 Apr; 101(8):3205-11. PubMed ID: 12506033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
    Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
    Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.
    Ismail MA; Samara M; Al Sayab A; Alsharshani M; Yassin MA; Varadharaj G; Vezzalini M; Tomasello L; Monne M; Morsi H; Qoronfleh MW; Zayed H; Cook R; Sorio C; Modjtahedi H; Al-Dewik NI
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1319. PubMed ID: 32700424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
    Luo Z; Gao M; Huang N; Wang X; Yang Z; Yang H; Huang Z; Feng W
    J Exp Clin Cancer Res; 2019 May; 38(1):224. PubMed ID: 31138265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical Study of SCIN Expression and Dromoter Methylation in Patients with Chronic Myeloid Leukemia].
    Zhang ZH; Lian XY; Li XX; He PF; Lin J; Qian J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):646-651. PubMed ID: 31204912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia.
    Della Peruta M; Martinelli G; Moratti E; Pintani D; Vezzalini M; Mafficini A; Grafone T; Iacobucci I; Soverini S; Murineddu M; Vinante F; Tecchio C; Piras G; Gabbas A; Monne M; Sorio C
    Cancer Res; 2010 Nov; 70(21):8896-906. PubMed ID: 20959494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK; Minden MD
    Biochem Biophys Res Commun; 1997 Apr; 233(3):806-12. PubMed ID: 9168938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.